DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)

Information source: Nycomed
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Common Cold

Intervention: xylometazoline hydrochloride and ipratropium bromide (ZyComb) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Nycomed

Official(s) and/or principal investigator(s):
Nycomed Clinical Trial Operations, Study Chair, Affiliation: Headquaters

Summary

The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting.

Clinical Details

Official title: A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- For inclusion the patient must buy ZyComb® nasal spray with the intention to start

using it either the same or the next day.

Locations and Contacts

Additional Information

Starting date: December 2006
Last updated: May 4, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017